Peer-reviewed veterinary case report
CDC6 gene found in dog blood may help detect tumors
By Andriessen, Anneloes et al.·Published in Veterinary and comparative oncology·2022·Department Biomolecular Health Sciences, Netherlands·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: CDC6: A novel canine tumour biomarker detected in circulating extracellular vesicles.
- Species:
- dog
Plain-English summary
A study found that a specific molecule called CDC6 can be detected in the blood of dogs with tumors, making it a potential new way to diagnose cancer without needing a tissue biopsy. Researchers looked at blood samples from 20 dogs with tumors and 20 healthy dogs, finding that CDC6 levels were much higher in the dogs with cancer. This suggests that testing for CDC6 in blood could help veterinarians identify tumors earlier and more easily. The results indicate that CDC6 could be a valuable tool for diagnosing cancer in dogs.
People also search for: dog cancer diagnosis blood test · CDC6 biomarker for dogs · non-invasive dog tumor detection
Abstract
Circulating nucleic acids and extracellular vesicles (EV) represent novel biomarkers to diagnose cancer. The non-invasive nature of these so-called liquid biopsies provides an attractive alternative to tissue biopsy-based cancer diagnostics. This study aimed to investigate if circulating cell cycle-related E2F target transcripts can be used to diagnose tumours in canine tumour patients with different types of tumours. Furthermore, we assessed if these mRNAs are localised within circulating EV. We isolated total RNA from the plasma of 20 canine tumour patients and 20 healthy controls. Four E2F target genes (CDC6, DHFR, H2AFZ and ATAD2) were selected based on the analysis of published data of tumour samples available in public databases. We performed reverse transcription and quantitative real-time PCR to analyse the plasma levels of selected E2F target transcripts. All four E2F target transcripts were detectable in the plasma of canine tumour patients. CDC6 mRNA levels were significantly higher in the plasma of canine tumour patients compared to healthy controls. A subset of canine tumour patient and healthy control plasma samples (n = 7) were subjected to size exclusion chromatography in order to validate association of the E2F target transcripts to circulating EV. For CDC6, EV analysis enhanced their detectability compared to total plasma analysis. In conclusion, our study reveals circulating CDC6 as a promising non-invasive biomarker to diagnose canine tumours.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/34743398/